Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Sterile Injectables CDMO Market Poised To Hit $10.91 Billion By 2030 With A 10.3% CAGR
The sterile injectables CDMO market has shown rapid expansion in recent years. This market is anticipated to grow from $6.65 billion in 2025 to $7.36 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. The historical growth of this market can be attributed to several factors including limited CDMO infrastructure for sterile injectables, a growing demand for small molecule injectables, the reliance on in-house formulation development, increasing regulatory scrutiny for sterile manufacturing, and rising global pharmaceutical production.
The sterile injectables cdmo market is projected to experience swift expansion over the coming years. This market is set to reach $10.91 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.3%. Factors contributing to this growth include the expansion of large molecule biologics manufacturing, the rising need for cell and gene therapies, the implementation of advanced aseptic processing techniques, increased outsourcing to cdmos, and the growing requirements for specialized packaging and cold chain storage. Key developments anticipated during this period involve an escalating demand for contract manufacturing of sterile injectables, the broadening of analytical and testing services for quality assurance, an increase in the production of monoclonal antibodies, peptides, and cell/gene therapy, a greater embrace of lyophilized, emulsion, and reconstitutable injectable formulations, and the unification of formulation development with packaging and storage offerings.
Get A Free Sample Report With In-Depth Market Insights:
Sterile Injectables CDMO Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding requirement for biologics and biosimilars is projected to propel the growth of the sterile injectables CDMO market moving forward. Biologics are medicinal products derived from living cells or organisms, designed to target specific disease elements, whereas biosimilars are almost identical versions of approved biologics, matching them in terms of quality, safety, and efficacy. The heightened need for biologics and biosimilars stems from the increasing prevalence of chronic and intricate health conditions, as these advanced therapies provide more focused and potent treatment options compared to conventional medicines. This escalating demand for biologics and biosimilars leads to a greater dependence on sterile injectable CDMO services, given that these treatments are commonly administered through injection and necessitate meticulously maintained sterile conditions to guarantee safety, quality, and compliance with regulations. For example, in February 2025, according to the Center for Biosimilars, a US-based nonprofit research organization, the US allocated an estimated US $324 billion to biologic medicines in 2023, constituting approximately 45% of the nation’s overall prescription drug expenditure. Consequently, the rising demand for biologics and biosimilars is fostering the expansion of the sterile injectables CDMO market.
Sterile Injectables CDMO Market Segment Landscape: Which Areas Lead Development?
The sterile injectables cdmo market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Service: Formulation Development, Analytical And Testing Services, Manufacturing, Packaging, Storage, Other Services
3) By Route Of Administration: Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Other Routes Of Administration
4) By Therapeutic Area: Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases, Other Therapeutic Areas
5) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Research Institutes, Other End-Users
Subsegments:
1) By Small Molecule: Solutions, Suspensions, Lyophilized Injectables, Emulsions, Reconstitutable Powders
2) By Large Molecule: Monoclonal Antibodies (mAbs), Peptides And Proteins, Vaccines, Cell And Gene Therapies, Insulins And Biosimilars
#Sterile Injectables CDMO Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the Sterile Injectables CDMO market are concentrating on creating advanced solutions, specifically modular aseptic filling platforms, to improve adaptability and productivity in sterile drug manufacturing. These platforms represent adaptable isolator-based sterile filling systems, constructed from interchangeable modules, which allow CDMOs to readily alternate between vial, syringe, or cartridge formats. This capability helps in shortening changeover times, reducing product wastage, and effectively managing small- to mid-scale batches for both clinical and commercial sterile injectables. As an illustration, in February 2025, Recipharm AB, a CDMO based in Sweden, unveiled a fully operational modular sterile filling system at its Wasserburg, Germany facility. This system is designed for the aseptic filling of small to mid-scale batches (ranging from 500–50,000 units), minimizes product loss to less than 500 milliliters, supports various interchangeable filling modules, and enables the efficient processing of high-value biologics within a complete isolator environment.
Sterile Injectables CDMO Market Industry Leaders And Competitive Landscape
Major companies operating in the sterile injectables cdmo market are Pfizer Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim, Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotechnology Inc.
View The Full Sterile Injectables CDMO Market Report:
Sterile Injectables CDMO Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the sterile injectables CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile injectables cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model